On-Demand CME Videos
What Dermatologist Need to Know about Chronic Spontaneous Urticaria and the Role of Biologics
About
This activity was recorded at the Fall Clinical Dermatology Conference 2023.
What Dermatologist Need to Know about Chronic Spontaneous Urticaria and the Role of Biologics
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Availability
In order to ensure educational material is relevant, educational materials will expire after a certain time period. This course will be available for the following dates:
December 6, 2023
December 31, 2024
Learning Objectives
At the completion of this activity, participants should be better able to:
Describe strategies to diagnose patients with CSU
Describe the role of biologics for the management of CSU
Identify strategies to incorporate biologics for the management of CSU into everyday dermatology practice
Intended Audience
Faculty
Mark Lebwohl, MD
Dean for Clinical Therapeutics
Waldman Professor
Chairman Emeritus
Kimberly and Eric J. Waldman Department of Dermatology
Icahn School of Medicine at Mount Sinai
New York, NY
G. Michael Lewitt, MD
Dermatologist
Illinois Dermatology Institute
Chicago, IL
Dawn Merritt, DO
Dermatology Residency Program Director
OhioHealth Riverside Hospital
Columbus, OH
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada, Reno School of Medicine and CMEsquared. The University of Nevada, Reno School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada, Reno School of Medicine designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: Abbvie, Amgen, Arcutis, Avotres, Boehringer Ingelheim, Cara Therapeutics, Dermavant Sciences, Eli Lilly, Incyte, Inozyme, Janssen Research & Development, LLC, Novartis, Ortho Dermatologics, Regeneron, and UCB, Inc.
Consultant: AnaptysBio, Arcutis, Inc., Arena Pharmaceuticals, Aristea Therapeutics, Avotres Therapeutics, BioMX, Boehringer-Ingelheim, Brickell Biotech, Cara Therapeutics, Castle Biosciences, Corevitas, Dermavant Sciences, Evommune, Inc., Facilitation of International Dermatology Education, Hexima Ltd., Meiji Seika Pharma, Mindera, National Society of Cutaneous Medicine, New York College of Podiatric Medicine, Pfizer, Seanergy, SUN Pharma, Verrica, and Vial.
Advisory Board: Dermavant, Pfizer, Galderma, Janssen, Lilly, UCB Grant/Research Support: Amgen, Abbvie, Lilly, DermTech, Dermavant, Aobiome, Novan
Consultant: Dermavant, Pfizer, Galderma, Janssen, Lilly, UCB Speakers’ Bureau or Honoraria: Abbvie, Arcutis, Lilly, Janssen, Pfizer, Dermavant, BMS, Incyte, UCB, Orthodermatologics
Consultant: Abbvie, Arcutis, BMS, Dermavant, Lilly, Novartis, UCB
Speaker's Bureau or Honoraria: Abbvie, Amgen, BMS, Dermavent, LEO, Lilly, Pfizer
The University of Nevada, Reno School of Medicine discloses that all relevant conflicts have been satisfactorily mitigated.